Bank of Montreal’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $142K | Hold |
51,923
| – | – | ﹤0.01% | 3036 |
|
|
2025
Q4 | $192K | Buy |
51,923
+10,045
| +24% | +$32.5K | ﹤0.01% | 2866 |
|
|
2025
Q3 | $111K | Buy |
+41,878
| New | +$81K | ﹤0.01% | 2942 |
|
|
2024
Q4 | – | Sell |
-3,030
| Closed | -$5.09K | – | 3629 |
|
|
2024
Q3 | $5.09K | Sell |
3,030
-426,822
| -99% | -$862K | ﹤0.01% | 3718 |
|
|
2024
Q2 | $959K | Buy |
429,852
+378,952
| +745% | +$891K | ﹤0.01% | 2044 |
|
|
2024
Q1 | $139K | Buy |
+50,900
| New | +$124K | ﹤0.01% | 3199 |
|
|
2021
Q2 | – | Sell |
-1,185
| Closed | -$33K | – | 4045 |
|
|
2021
Q1 | $33K | Sell |
1,185
-3,228
| -73% | -$95.2K | ﹤0.01% | 3867 |
|
|
2020
Q4 | $139K | Sell |
4,413
-26,886
| -86% | -$805K | ﹤0.01% | 3409 |
|
|
2020
Q3 | $1.09M | Sell |
31,299
-11,142
| -26% | -$441K | ﹤0.01% | 1931 |
|
|
2020
Q2 | $2.19M | Buy |
42,441
+41,866
| +7,281% | +$1.75M | ﹤0.01% | 1599 |
|
|
2020
Q1 | $19K | Sell |
575
-3,187
| -85% | -$168K | ﹤0.01% | 3262 |
|
|
2019
Q4 | $224K | Buy |
3,762
+1,000
| +36% | +$45K | ﹤0.01% | 3100 |
|
|
2019
Q3 | $101K | Buy |
2,762
+91
| +3% | +$3.6K | ﹤0.01% | 3286 |
|
|
2019
Q2 | $125K | Buy |
2,671
+2,096
| +365% | +$98.4K | ﹤0.01% | 3205 |
|
|
2019
Q1 | $23K | Sell |
575
-323
| -36% | -$14.5K | ﹤0.01% | 3623 |
|
|
2018
Q4 | $41K | Buy |
898
+165
| +23% | +$7.95K | ﹤0.01% | 3355 |
|
|
2018
Q3 | $33K | Sell |
733
-5
| -0.7% | -$230 | ﹤0.01% | 3547 |
|
|
2018
Q2 | $29K | Buy |
738
+163
| +28% | +$8.24K | ﹤0.01% | 3617 |
|
|
2018
Q1 | $42K | Sell |
575
-7,021
| -92% | -$516K | ﹤0.01% | 3303 |
|
|
2017
Q4 | $500K | Buy |
7,596
+6,000
| +376% | +$323K | ﹤0.01% | 2279 |
|
|
2017
Q3 | $80K | Buy |
1,596
+1,000
| +168% | +$48.2K | ﹤0.01% | 3068 |
|
|
2017
Q2 | $28K | Sell |
596
-6,000
| -91% | -$221K | ﹤0.01% | 3408 |
|
|
2017
Q1 | $233K | Buy |
6,596
+6,000
| +1,007% | +$137K | ﹤0.01% | 2394 |
|
|
2016
Q4 | $6K | Sell |
596
-98
| -14% | -$1.17K | ﹤0.01% | 3712 |
|
|
2016
Q3 | $10K | Sell |
694
-21,041
| -97% | -$238K | ﹤0.01% | 3548 |
|
|
2016
Q2 | $215K | Buy |
21,735
+12,834
| +144% | +$213K | ﹤0.01% | 2440 |
|
|
2016
Q1 | $150K | Buy |
8,901
+2,389
| +37% | +$38.4K | ﹤0.01% | 2614 |
|
|
2015
Q4 | $144K | Buy |
6,512
+6,129
| +1,600% | +$155K | ﹤0.01% | 2595 |
|
|
2015
Q3 | $9K | Buy |
383
+133
| +53% | +$8.35K | ﹤0.01% | 3490 |
|
|
2015
Q2 | $20K | Sell |
250
-2,354
| -90% | -$230K | ﹤0.01% | 3304 |
|
|
2015
Q1 | $241K | Buy |
2,604
+1,750
| +205% | +$113K | ﹤0.01% | 2276 |
|
|
2014
Q4 | $35K | Hold |
854
| – | – | ﹤0.01% | 3164 |
|
|
2014
Q3 | $21K | Buy |
854
+744
| +676% | +$11.8K | ﹤0.01% | 3448 |
|
|
2014
Q2 | $2K | Buy |
+110
| New | +$1.59K | ﹤0.01% | 4483 |
|
Other funds holding ESPR
WA
TSC
O
VCM
Bank of Montreal's ESPR Position: Q1 2026 in Review
Bank of Montreal held its Esperion Therapeutics (ESPR) position steady in Q1 2026 at 51,923 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.
Bank of Montreal first reported a position in ESPR in Q2 2014 and has held it in 34 quarters since. The position peaked at $2.19M in Q2 2020. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.
- Bank of Montreal held 51,923 shares of Esperion Therapeutics worth $142K as of Q1 2026.
- Bank of Montreal left its Esperion Therapeutics share count unchanged in Q1 2026.
- Esperion Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #3036 holding.
- Bank of Montreal first reported a position in Esperion Therapeutics in Q2 2014 and has held it in 34 quarters since.
- Bank of Montreal's Esperion Therapeutics position peaked at $2.19M in Q2 2020.
- 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.